Gefitinib may be effective to treat esophageal cancer in some patients
the ONA take:
According to new research published in The Lancet Oncology, gefitinib, a drug already used to treat lung cancer, may be effective to treat esophageal cancer in a small subgroup of patients. In the Cancer Oesophagus Gefitinib study, researchers tested gefitinib in patients with esophageal cancer who had progressed after chemotherapy.
The study showed that gefitinib had minimal impact on most patients and only increased survival rates by a small amount; however, the drug did drastically improve the quality of life, survival duration, and symptom control in about 15% of patients. The main adverse effect was diarrhea.
Russell Petty, PhD, of the University of Aberdeen in Aberdeen, Scotland and senior researcher of the study said that the patients who improved on gefitinib did so within a few weeks of initiating therapy and some patients had disease control for almost 2 years. Dr. Petty notes that not all patients with esophageal cancer should be offered gefitinib and that there is a need for a test to screen whether a patient would improve on gefitinib.
Gefitinib (Iressa), a tyrosine kinase inhibitor, was approved in 2003 by the U.S. Food and Drug Administration to treat advanced EGFR mutation-positive non-small cell lung cancer.
Findings of a trial could lead to a new treatment approach for oesophageal cancer.
The University of Aberdeen was involved in a UK wide study to see if the drug gefitinib - already used in lung cancer - could help treat oesophageal cancer.
The Cancer Oesophagus Gefitinib trial was the first study conducted in oesophageal cancer patients whose disease had progressed after chemotherapy.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- Breast Conservation Improves Survival vs Mastectomy in Breast Cancer
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|